Why the study?
Does targeting a higher hemoglobin level (13.5-14.5 g/dl) with epoetin alfa improve quality of life compared to a lower target (9.5-11.5 g/dl) in incident hemodialysis patients without symptomatic cardiac disease?
Does targeting a higher hemoglobin level (13.5-14.5 g/dl) with epoetin alfa improve quality of life compared to a lower target (9.5-11.5 g/dl) in incident hemodialysis patients without symptomatic cardiac disease?
In relatively healthy hemodialysis patients, targeting normal hemoglobin levels (13.5-14.5 g/dl) with epoetin alfa significantly improves fatigue compared to lower targets.
No takes yet. Share an insight, caveat, or question.
Supports higher hemoglobin targets to ease fatigue in incident hemodialysis patients without cardiac disease; extends quality-of-life evidence for anemia management.
Foley et al. (2009) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: